1. Home
  2. MESO

as 10-22-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Founded: 2004 Country:
Australia
Australia
Employees: N/A City: N/A
Market Cap: 1.1B IPO Year: N/A
Target Price: $11.50 AVG Volume (30 days): 208.8K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.09 EPS Growth: N/A
52 Week Low/High: $1.61 - $11.05 Next Earning Date: 08-28-2024
Revenue: $5,902,000 Revenue Growth: -21.32%
Revenue Growth (this year): 66.05% Revenue Growth (next year): 348.27%

MESO Daily Stock ML Predictions

Share on Social Networks: